Autologous Dressing Production Set with Rough Surface
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current wound dressings are not tailored to the size and shape of the wound, do not accelerate healing, cause pain and allergic reactions, and require frequent changes, leading to prolonged treatment times and increased costs.
Innovation Solution
A set and method for producing autologous dressings from a patient's blood, using a shaping container and cover made of stainless steel with a rough surface, which separates into two fibrin fractions (I-PRF and S-PRF) to create a gel-like dressing that fits the wound's shape and size, accelerating healing and reducing scarring and allergic reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional wound dressings are used, then they provide basic protective function, but they do not accelerate healing and require frequent changes
Solution Approach 1:
The patent changes the biochemical composition parameters by using autologous platelet-rich plasma and fibrin fractions, transforming the dressing from inert to biologically active. This enables accelerated wound healing while reducing the need for frequent replacements, as the dressing actively participates in the healing process rather than merely providing protection.
Solution Approach 2:
The dressing uses the patient's own blood components (platelets, fibrin) to promote healing, making the system self-sustaining. The growth factors and coagulation factors within the dressing continuously stimulate wound repair without requiring external intervention or frequent replacement, embodying the self-service principle.
2Adaptability or versatility
If standard dressings are applied, then they cover the wound surface, but they do not adapt to the specific shape and size of the wound
Solution Approach 1:
The patent applies local quality by customizing the dressing to match the specific wound's geometry. The shaping container with its specifically designed geometry allows the dressing to be molded into the exact shape and size needed, providing localized adaptation rather than using a generic dressing design.
Solution Approach 2:
The patent segments the wound care process into collection, separation, and application stages, allowing the dressing to be precisely tailored to each patient's wound. The modular approach with different shaping container types enables customization for various wound configurations.
3Shape
If mechanical pressure is applied to shape the fibrin clot, then the dressing takes the desired form, but the cells contained in the clot are destroyed
Solution Approach 1:
The patent replaces mechanical pressure with a chemical solution approach. Instead of mechanically compressing the fibrin clot to shape it, the invention uses a chemical solution that penetrates the clot and modifies its properties, allowing the dressing to be shaped through chemical action rather than mechanical force, thereby preserving cell viability.
Solution Approach 2:
The patent introduces a chemical solution as an intermediary between the fibrin clot and the shaping process. This chemical mediator allows the clot to be shaped without direct mechanical contact, protecting the embedded cells from destruction while still achieving the desired form.
4Strength
If synthetic components are used in dressings, then they provide structural integrity, but they cause allergic reactions and do not promote natural healing
Solution Approach 1:
The patent fundamentally changes the material composition from synthetic to autologous biological materials. By using the patient's own platelets and fibrin, the dressing eliminates allergic reactions to foreign substances while maintaining structural integrity through the natural properties of fibrin and platelet-derived growth factors.
Solution Approach 2:
The dressing is made from the patient's own blood components, making the body's own substances serve the protective and healing functions. This self-service approach eliminates the harmful factor of allergic reactions to synthetic materials, as the immune system recognizes the autologous components as self.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The autologous dressing significantly shortens wound healing time by approximately 50%, reduces treatment costs, minimizes pain, and prevents bacterial infections, while maintaining wound integrity and mobility.
Implementation Method 1
the blood collected from the subject is separated into two volumes, preferably two substantially equal volumes; from the first volume, the cell-rich fibrin fraction (I-PRF) is obtained by centrifugation from 50 RCF (xg) to 70 RCF (xg) for 3 to 5 minutes; from the second volume, the S-PRF structural fibrin fraction is obtained by centrifugation at 600 RCF (xg) to 800 RCF (xg) for 8 to 16 minutes
Implementation Method 2
to produce an autologous dressing, the set for producing autologous tissue dressings with combined I-PRF and S-PRF fractions is set aside for the time needed to make the gel form
Data Source
Figure 1A~1G
Figure 2A~3D
Figure 4A~5E
AI summary
The invention relates to a set for producing an autologous dressing from blood, which comprises a shaping container (1) and a cover (2) of the shaping container with a shape and size resulting from the n-series of types; the shaping container (1) has a substantially flat base (5), side walls (6), the cover (2) has a lid (7) and side walls (8); the cover (2) is matched in shape and size to the shaping container (1), the shaping container (1) is made of stainless steel and at least the bottom surface of the shaping container has a rough surface (9) from the inside, with a roughness degree in the range of 0.01-100 µm. The invention also relates to a method of production of the autologous dressing from the blood of a subject, in which the autologous dressing is produced in the set by combining a cell-rich fibrin fraction (I-PRF) with a structural fibrin fraction (S-PRF). The invention also relates to the produced autologous dressing from the blood of a subject and its use for the treatment of wounds, especially a wound in diabetes, diabetic foot, burns, pressure sores, frostbite, postoperative, and ulcerative wounds in a subject.